Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax) and Trastuzumab in High-risk HER2+ Breast Cancer Patients
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Dec 2017
At a glance
- Drugs Nelipepimut-S (Primary) ; Sargramostim; Trastuzumab
- Indications Breast cancer
- Focus Therapeutic Use
- 29 Dec 2017 According to a Sellas Life Sciences Group media release, SELLAS Life Science Group acquired Galena Biopharma, and subsequently Galena Biopharma changed its name to SELLAS Life Science Group.
- 28 Sep 2017 According to a Galena Biopharma media release, results from the primary endpoint of the trial are expected in the fourth quarter of 2019.
- 28 Sep 2017 Status changed from recruiting to active, no longer recruiting according to a Galena Biopharma media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History